Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia

Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

(2011) A. Willer et al.   BLOOD

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

(2011) J. D. Kawedia et al.   BLOOD

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia

(2011) Jun J Yang et al.   NATURE GENETICS

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia

(2010) J. D. Kawedia et al.   BLOOD

Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity

(2010) S-H Chen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

(2009) Ching-Hon Pui et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia

(2008) M. L. te Winkel et al.   HAEMATOLOGICA

Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia

(2008) Lei Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

A mouse model for glucocorticoid-induced osteonecrosis: Effect of a steroid holiday

(2008) Lei Yang et al.   JOURNAL OF ORTHOPAEDIC RESEARCH